Public articles linked to the same research event.
medRxiv In 1,095 carriers of pathogenic or likely pathogenic sarcomere variants across three international centers, a previously validated AI-ECG model applied to 12-lead ECG images yielded an AUROC of 0.91 for the HCM phenotype at baseline and 0.92 for manifest HCM, a higher AI-ECG score among genotype-positive/phenotype-negative individuals predicted incident HCM during follow-up (unadjusted HR 1.55 per 1-SD; adjusted HR 1.38), and in 57,007 UK Biobank participants the AI-ECG score and a polygenic risk score were independent and additive, with adjusted odds of HCM of 60.2 when both were high.
In 1,095 carriers of pathogenic or likely pathogenic sarcomere variants across three international centers, a previously validated AI-ECG model applied to 12-lead ECG images yielded an AUROC of 0.91 for the HCM phenotype at baseline and 0.92 for manifest HCM, a higher AI-ECG score among genotype-positive/phenotype-negative individuals predicted incident HCM during follow-up (unadjusted HR 1.55 per 1-SD; adjusted HR 1.38), and in 57,007 UK Biobank participants the AI-ECG score and a polygenic risk score were independent and additive, with adjusted odds of HCM of 60.2 when both were high.
In 1,095 carriers of pathogenic or likely pathogenic sarcomere variants across three international centers, a previously validated AI-ECG model applied to 12-lead ECG images yielded an AUROC of 0.91 for the HCM phenotype at baseline and 0.92 for manifest HCM, a higher AI-ECG score among genotype-positive/phenotype-negative individuals predicted incident HCM during follow-up (unadjusted HR 1.55 per 1-SD; adjusted HR 1.38), and in 57,007 UK Biobank participants the AI-ECG score and a polygenic risk score were independent and additive, with adjusted odds of HCM of 60.2 when both were high.
In 1,095 carriers of pathogenic or likely pathogenic sarcomere variants across three international centers, a previously validated AI-ECG model applied to 12-lead ECG images yielded an AUROC of 0.91 for the HCM phenotype at baseline and 0.92 for manifest HCM, a higher AI-ECG score among genotype-positive/phenotype-negative individuals predicted incident HCM during follow-up (unadjusted HR 1.55 per 1-SD; adjusted HR 1.38), and in 57,007 UK Biobank participants the AI-ECG score and a polygenic risk score were independent and additive, with adjusted odds of HCM of 60.2 when both were high.